ORI Capital, the venture firm behind CG's big IPO, raises new biotech fund
BioPharma
Stay updated with breaking news from Simone Song. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ORI Capital today announced the final close of its second fund, ORI Fund II (the "Fund"), with total commitments of $260 million. This milestone meets the Fund's original target and underscores strong investor confidence in ORI Capital's investment...
CG Oncology Inc. believes it has developed the right treatments for bladder cancer. So does Wall Street.
CG Oncology Inc. has spent more than a decade trying to find solutions to bladder cancer. Investors believe the researcher is getting closer.
CG Oncology, an oncolytic immunotherapy company, has raised $120m through Series E financing round to advance its lead clinical programmes in bladder cancer towards FDA approval.